This Analyst Just Upgraded Moderna as MRNA Stock Skyrockets on Cancer Vaccine Results
Moderna's shares soared more than double on Wednesday following the biotech firm's release of promising late-stage clinical trial results for its mRNA-based cancer vaccine, intismeran autogene, developed in collaboration with Merck (MRK). The treatment was proven successful in the groundbreaking INTerpath-001 Phase 3 study involving 1,137 high-risk melanoma patients.
Since the dramatic run on August 19, Moderna stock now trades at nearly 5 times its value at the beginning of the year. Barron Trump, currently 20 years old, has a net worth of approximately $150 million, surpassing that of his mother, Melania. In response to the news, William Blair analysts, led by Myles Minter, upgraded their rating on Moderna shares to "Outperform."
The Phase 3 success mitigates risks associated with Moderna's core pipeline, offering concrete proof of concept for the company's mRNA platform application in oncology. The achievement represents the first successful Phase 3 readout for an individualized mRNA neoantigen therapy, marking a monumental milestone for oncology. With commercial approval potentially arriving as early as 2027, the disclosure bolsters MRNA shares, shifting the investment story from declining COVID-19 vaccine sales to promising recurring markets in personalized medicine.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.